



27th December 2012

Aurobindo Pharma receives final approvals for Nafcillin Injections

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Nafcillin for Injection USP, packaged in 1g and 2g vials (ANDA 091613) and Nafcillin for Injection USP 10g/Vial Pharmacy Bulk Package (ANDA 091614). The products are ready for launch.

Nafcillin for Injection is a sterile semisynthetic penicillin (SSP) indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. It may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results.

These ANDAs have been approved out of Unit XII formulation facility in Hyderabad, India and will be marketed and sold by Aurobindo's US subsidiary AuroMedics Pharma LLC

Aurobindo now has a total of 171 ANDA approvals (145 Final approvals including 2 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com